These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 33139290)

  • 41. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
    Chatterjee S
    Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.
    Zhang L; Zhang D; Wang X; Yuan C; Li Y; Jia X; Gao X; Yen HL; Cheung PP; Huang X
    Phys Chem Chem Phys; 2021 Mar; 23(10):5852-5863. PubMed ID: 33688867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-Target
    Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice.
    Carlin AF; Beadle JR; Ardanuy J; Clark AE; Rhodes V; Garretson AF; Murphy JA; Valiaeva N; Schooley RT; Frieman MB; Hostetler KY
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0103924. PubMed ID: 39240093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remdesivir: From Ebola to COVID-19.
    Santoro MG; Carafoli E
    Biochem Biophys Res Commun; 2021 Jan; 538():145-150. PubMed ID: 33388129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacodynamics of obeldesivir versus remdesivir.
    Faghihi I; Yan VC
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123
    [No Abstract]   [Full Text] [Related]  

  • 49. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.
    Singh PK; Pathania S; Rawal RK
    SAR QSAR Environ Res; 2020 Nov; 31(11):857-867. PubMed ID: 33100032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
    Saqrane S; El Mhammedi MA; Lahrich S; Laghrib F; El Bouabi Y; Farahi A; Bakasse M
    J Infect Public Health; 2021 May; 14(5):655-660. PubMed ID: 33857725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.
    Knapp RR; Tona V; Okada T; Sarpong R; Garg NK
    Org Lett; 2020 Nov; 22(21):8430-8435. PubMed ID: 33085486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
    Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Remdesivir, the antiviral hope against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2020 Jun; 33(3):176-179. PubMed ID: 32239125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
    Banerjee A; Kanwar M; Maiti S
    Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
    Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ
    Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Timing of remdesivir for COVID-19.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):161. PubMed ID: 33429407
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
    Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
    J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
    Sörgel F; Malin JJ; Hagmann H; Kinzig M; Bilal M; Eichenauer DA; Scherf-Clavel O; Simonis A; El Tabei L; Fuhr U; Rybniker J
    J Antimicrob Chemother; 2021 Feb; 76(3):825-827. PubMed ID: 33251541
    [No Abstract]   [Full Text] [Related]  

  • 60. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
    Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
    Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.